GALECTIN THERAPEUTICS, INC. SUBSCRIPTION AGREEMENTSubscription Agreement • December 29th, 2016 • Galectin Therapeutics Inc • Pharmaceutical preparations • Nevada
This Subscription Agreement pertains to the offering (the “Offering”) by Galectin Therapeutics, Inc. (the “Company”) of units (the “Units”), each such Unit consisting of one (1) share (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and warrants (the “Warrants”) to purchase in the aggregate seventy-five percent (75%) of one (1) share of Common Stock, which shall have an exercise price of Five Dollars ($5.00) per share of Common Stock, at a purchase price of $ per Unit (the “Unit Price”) as described in the Private Placement Offering Memorandum for the Units dated November, 2016, as the same hereto may be amended (the “Offering Memorandum”). The Company is making this Offering solely to “accredited investors” (as defined under Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended). This Offering is subject to one or more closing(s) of the sale of the Units (each a “Closing”), and a final closing of the sale of
SECOND AMENDMENT TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 29th, 2016 • Galectin Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS SECOND AMENDMENT (“Amendment”) dated December 23, 2016, to the SECURITIES PURCHASE AGREEMENT, dated as of September 22, 2016 (the “Agreement”), by and between GALECTIN THERAPEUTICS, INC., a Nevada corporation (the “Company”), and 10X FUND, L.P., a Delaware limited partnership (the “Purchaser”).
